PPARG and hepatocellular carcinoma: Using a diethylnitrosamine- (DEN-) induced hepatocarcinoma cell (HCC) model, the authors showed that activation of PPARγ by rosiglitazone blocked tumor development in PPARγ wild-type (PPARγ+/+) littermates, whereas it did not alter tumor formation in PPARγ+/− mice.